Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/refractory B cell non-Hodgkin lymphoma Journal Article

   

Authors:	Jain, T.; Sauter, C. S.; Shah, G. L.; Maloy, M. A.; Chan, J.; Scordo, M.; Avecilla, S. T.; Batlevi, Y.; Dahi, P. B.; Batlevi, C. W.; Lia Palomba, M.; Giralt, S. A.; Perales, M. A.
Article Title:	Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/refractory B cell non-Hodgkin lymphoma
Keywords:	adult; clinical article; treatment outcome; treatment response; fludarabine; lenalidomide; prednisone; cancer recurrence; case report; doxorubicin; cancer growth; gemcitabine; cancer radiotherapy; cytarabine; methotrexate; rituximab; cancer staging; neurotoxicity; letter; carboplatin; low drug dose; etoposide; maintenance therapy; cyclophosphamide; vincristine; ifosfamide; thiotepa; b cell lymphoma; chronic graft versus host disease; death; graft versus host reaction; transplantation conditioning; sepsis; allogeneic hematopoietic stem cell transplantation; corticosteroid; oxaliplatin; tacrolimus; marginal zone lymphoma; lymphadenopathy; alemtuzumab; subcutaneous nodule; budesonide; cytokine release syndrome; diffuse large b cell lymphoma; mycophenolic acid; ibrutinib; human; male; female; priority journal; chimeric antigen receptor t-cell immunotherapy; lisocabtagene maraleucel
Journal Title:	Leukemia
Volume:	33
Issue:	10
ISSN:	0887-6924
Publisher:	Nature Publishing Group
Date Published:	2019-10-01
Start Page:	2540
End Page:	2544
Language:	English
DOI:	10.1038/s41375-019-0476-y
PUBMED:	31114023
PROVIDER:	scopus
PMCID:	PMC8224498
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066140851&doi=10.1038%2fs41375-019-0476-y&partnerID=40&md5=984966a0dfc7e7f7b046c972ec17e538
Notes:	Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/155466